Bristol-Myers Squibb (BMY) director Phyllis R. Yale gains more deferred share units

Rhea-AI Filing Summary

Bristol-Myers Squibb director Phyllis R. Yale reported additional deferred share units tied to company stock. On 12/31/2025, she acquired 648.869 Deferred Share Units, each linked to one share of Bristol-Myers Squibb common stock at a $0 exercise price. After this transaction, she beneficially owned 38,891.933 deferred share units in total, held directly.

The deferred share units are part of the 1987 Deferred Compensation Plan for Non-Employee Directors and include both deferred compensation and dividends that have been reinvested. These units will convert into shares of common stock when she ceases to be a director or at a future date she previously selected, meaning the economic value is tied to the company’s share performance over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

YALE PHYLLIS R

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	12/31/2025		A		648.869		(1)	(1)	Common Stock, $0.10 par value	648.869	$0	38,891.933(2)	D

Explanation of Responses:

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Remarks:

	/s/ Amy Fallone, attorney-in-fact for Phyllis R. Yale	01/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Bristol-Myers Squibb (BMY) disclose for Phyllis R. Yale?

Director Phyllis R. Yale acquired 648.869 Deferred Share Units on 12/31/2025, each linked to Bristol-Myers Squibb common stock at a $0 exercise price.

How many Bristol-Myers Squibb (BMY) deferred share units does Phyllis R. Yale hold after this transaction?

Following the reported transaction, Phyllis R. Yale beneficially owned 38,891.933 deferred share units, held in a direct ownership form.

When do Phyllis R. Yale’s Bristol-Myers Squibb deferred share units convert into common stock?

Each Deferred Share Unit will be converted into a share of common stock upon settlement, which occurs when she ceases to be a director or at a future date she previously specified.

What plan governs Phyllis R. Yale’s deferred share units at Bristol-Myers Squibb (BMY)?

The holdings include amounts under the 1987 Deferred Compensation Plan for Non-Employee Directors, which also reflects dividends reinvested into additional units.

Are Phyllis R. Yale’s Bristol-Myers Squibb deferred share units a cash transaction?

The filing lists the exercise price as $0 for the Deferred Share Units, indicating they are part of a deferred compensation arrangement rather than a typical market purchase.

What type of security did Phyllis R. Yale receive from Bristol-Myers Squibb (BMY)?

She received Deferred Share Units, a form of derivative security that is ultimately settled in shares of common stock of Bristol-Myers Squibb.